Suppr超能文献

在澳大利亚,组织血压控制项目以预防中风:它们具有成本效益吗?

Organized blood pressure control programs to prevent stroke in Australia: would they be cost-effective?

机构信息

Monash University, Victoria, Australia.

出版信息

Stroke. 2012 May;43(5):1370-5. doi: 10.1161/STROKEAHA.111.634949. Epub 2012 Feb 23.

Abstract

BACKGROUND AND PURPOSE

High blood pressure (BP) is the most important modifiable stroke risk factor. Worldwide high BP in many people is uncontrolled or people are unaware of their BP status. We aimed to assess whether a program of organized multidisciplinary care and medication would be cost-effective for improving BP control for the prevention of stroke.

METHODS

A novel aspect was to simulate the intervention to match recent primary care initiatives (eg, new Medicare reimbursement items) to ensure policy relevance. Current practice and additional costs of each intervention were included using the best available evidence. The differences in the cost per quality-adjusted life year (QALY) gained for the interventions were compared against current practice. Cost-effectiveness was defined as cost per QALY gained was less than Australian dollars (AUD) 50 000 (societal perspective; reference year 2004). The robustness of estimates was assessed with probabilistic multivariable uncertainty analysis.

RESULTS

For primary prevention, the median cost per QALY gained was AUD11 068 (95% uncertainty interval AUD5201 to AUD18 696) in those aged 75 years or older and was AUD17 359 (95% uncertainty interval AUD10 516 to AUD26 036) in those aged 55 to 84 years with ≥15% absolute risk of stroke. Primary prevention interventions were not cost-effective if aged younger than 50 years. The median cost per QALY gained for secondary prevention was AUD1811 and AUD4704, depending on which medications were modeled.

CONCLUSIONS

Organized care for BP control targeted at specific populations offers excellent value over current practice. Organized care for secondary prevention provided the greatest benefits and strongest cost-effectiveness. Translation into clinical practice requires improved use of relevant Medicare policy in Australia.

摘要

背景与目的

高血压(BP)是最重要的可改变的中风危险因素。在世界范围内,许多人的高血压未得到控制,或者他们不知道自己的血压状况。我们旨在评估有组织的多学科护理和药物治疗方案是否可以通过改善血压控制来降低中风风险,从而具有成本效益。

方法

一个新颖的方面是模拟干预措施,以匹配最近的初级保健计划(例如,新的医疗保险报销项目),以确保政策相关性。使用最佳可用证据纳入了当前实践和每种干预措施的额外成本。将干预措施的每获得一个质量调整生命年(QALY)的成本差异与当前实践进行了比较。成本效益被定义为每获得一个 QALY 的成本低于 50000 澳元(澳大利亚元;社会视角;参考年 2004 年)。通过概率多变量不确定性分析评估了估计值的稳健性。

结果

对于一级预防,对于 75 岁或以上的人群,每获得一个 QALY 的中位成本为 11068 澳元(95%不确定区间 5201 澳元至 18696 澳元),而对于年龄在 55 至 84 岁且中风风险≥15%的人群,每获得一个 QALY 的中位成本为 17359 澳元(95%不确定区间 10516 澳元至 26036 澳元)。如果年龄小于 50 岁,一级预防干预措施则不具有成本效益。二级预防的每获得一个 QALY 的中位成本分别为 1811 澳元和 4704 澳元,具体取决于所建模的药物。

结论

针对特定人群的 BP 控制的有组织护理提供了比当前实践更好的价值。针对二级预防的有组织护理提供了最大的益处和最强的成本效益。要将其转化为临床实践,需要在澳大利亚更好地利用相关的医疗保险政策。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验